NMS Capital Portfolio Company Flourish Research Announces Partnership with Merritt Island Medical Research, Further Expanding Presence in Neuroscience

New York, NY, November 14, 2023 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish”) announced today that it has partnered with Merritt Island Medical Research (“MIMR” or the “Company”). MIMR is a leading clinical research site located in Merritt Island, Florida that specializes in neuroscience related indications including Alzheimer’s Disease. The partnership represents the […]

Read More »

NMS Capital Portfolio Company Flourish Research Announces Partnership with Valley Clinical Trials Marking the Ninth Acquisition Since the Formation of Flourish in 2021

New York, NY, September 15, 2023 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish”) is pleased to announce the acquisition of Valley Clinical Trials (“Valley” or the “Company”). Valley is a leading clinical research site with three locations in California that specialize in cardiology, metabolic, and related therapeutic areas. The partnership represents the ninth acquisition since […]

Read More »

NMS Capital Portfolio Company Flourish Research Announces Partnerships with AMC Research and Central Research Associates

New York, NY, May 18, 2023 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish” or the “Company”) announced today that it has partnered with company management in the recapitalizations of AMC Research, LLC (“AMC”) and Central Research Associates (“CRA”), which are both leading clinical research sites that further establish Flourish as one of the […]

Read More »

NMS Capital Portfolio Company Flourish Research Announces Partnership with Suncoast Research Group

New York, NY, December 16, 2022 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish”) is pleased to announce the acquisition of Suncoast Research Group, LLC (“Suncoast” or the “Company”). Suncoast is a leading, multi-therapeutic clinical research site based in Miami, Florida. The transaction marks the sixth investment and partnership for Flourish Research, which was […]

Read More »

NMS Capital Portfolio Company Flourish Research Announces Partnership with Keystone Clinical Studies

New York, NY, October 6, 2022 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish”) announced today that it has partnered with company management in the recapitalization of Keystone Clinical Studies, LLC (“Keystone”). Keystone is a leading clinical research site focused on Alzheimer’s Disease and other conditions related to the Central Nervous System. The site […]

Read More »

NMS Capital Portfolio Company Flourish Research Announces Partnerships with Great Lakes Clinical Trials and Clinical Site Partners, Creating One of the Largest Clinical Site Networks in the United States

New York, NY, January 12, 2022 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish” or the “Company”) announced today that it has partnered with company management in the recapitalizations of Great Lakes Clinical Trials (“Great Lakes”) and Clinical Site Partners (“CSP”), which are both leading clinical research sites. The transactions mark the third and […]

Read More »

NMS Capital Portfolio Company Flourish Research Announces Investment in Excel Medical Clinical Trials

New York, NY, October 14, 2021 – NMS Capital (“NMS”) portfolio company Flourish Research (“Flourish”) announced today that it has partnered with company management in the recapitalization of Excel Medical Clinical Trials, LLC (“Excel”). Excel is a leading clinical research site focused on Cardiology and related conditions serving leading pharmaceutical companies and CROs founded in […]

Read More »

NMS Capital Announces Formation of Flourish Research and Investment in Clinical Trials of Texas

New York, NY, August 12, 2021 – NMS Capital (“NMS”) announced today that it has formed Flourish Research (“Flourish”), which will aim to become a leading, nationwide network of clinical research sites with therapeutic area and clinical trial phase diversity. For its initial investment in Flourish Research, NMS has completed the recapitalization of Clinical Trials […]

Read More »